Pregnancy in Osteogenesis Imperfecta (OI) Registry

Sponsor
University of South Florida (Other)
Overall Status
Completed
CT.gov ID
NCT03072303
Collaborator
Rare Diseases Clinical Research Network (Other), National Institutes of Health (NIH) (NIH)
170
1
26.9
6.3

Study Details

Study Description

Brief Summary

The purpose of this study is to learn about pregnancy outcomes in osteogenesis imperfecta (OI). Patients enrolled in the Brittle Bone Disorders (BBD) Contact Registry (CR) will be invited via email to participate in this study.

Condition or Disease Intervention/Treatment Phase
  • Other: Web-based Survey

Detailed Description

Population: The RDCRN BBD Contact Registry helps researchers identify and recruit patients who are eligible for participation in future research studies. People eligible for enrollment in the RDCRN BBD Contact Registry include patients and parents of patients with Brittle Bone Disorders. All patients with BBD from the United States and around the world are encouraged to join.

Survey Administration: The investigators will administer a review of pregnancy outcomes survey and delineate the outcomes in pregnancies complicated by varying forms of OI. Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.

Data: The survey data will be collected and stored at the Rare Diseases Clinical Research Network's Data Management and Coordinating Center (DMCC) at the University of South Florida. All data collected will be sent to the database of Genotypes and Phenotypes (dbGaP) to be stored indefinitely.

Study Design

Study Type:
Observational
Actual Enrollment :
170 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Pregnancy in Osteogenesis Imperfecta (OI) Registry
Actual Study Start Date :
Jun 16, 2017
Actual Primary Completion Date :
Mar 13, 2019
Actual Study Completion Date :
Sep 13, 2019

Outcome Measures

Primary Outcome Measures

  1. Pregnancy in OI Assessment [1 year]

    The goal of this survey is to characterize the course and outcome of pregnancy in individuals with OI. This is a self-report survey that will review pregnancy outcomes (maternal and fetal). Measures of pregnancy outcome will include 1) length of gestation, 2) mode of delivery, 3) neonatal outcomes including birth weight and length, 4) history of back pain or hip pain and or fractures during pregnancy or postpartum 5) number of maternal hospital admissions 6) calcium and vitamin D intake, 7) neonatal complications and 8) OI status in the fetus. One survey will be completed for each gestation (pregnancy).

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female with OI who has delivered an infant of at least 24 weeks' gestation

  • Participant in the BBD Contact Registry

Exclusion Criteria:
  • Inability to provide informed consent and complete survey

  • Males

  • Women with OI who have not delivered children and gestations associated with higher order multiples

Contacts and Locations

Locations

Site City State Country Postal Code
1 RDCRN Data Management and Coordinating Center, University of South Florida Tampa Florida United States 33612

Sponsors and Collaborators

  • University of South Florida
  • Rare Diseases Clinical Research Network
  • National Institutes of Health (NIH)

Investigators

  • Principal Investigator: Jeffrey Krischer, Ph.D., University of South Florida
  • Principal Investigator: Deborah Krakow, M.D., University of California, Los Angeles

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of South Florida
ClinicalTrials.gov Identifier:
NCT03072303
Other Study ID Numbers:
  • BBD7705
  • U01TR001263
First Posted:
Mar 7, 2017
Last Update Posted:
Oct 16, 2019
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of South Florida
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 16, 2019